|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7947295||NOVARTIS||Ophthalmic compositions containing a synergistic combination of two polymers|| |
(8 months from now)
|US9662398||NOVARTIS||Carboxylvinyl polymer-containing nanoparticle suspensions|| |
(7 years from now)
|US8921337||NOVARTIS||Carboxyvinyl polymer-containing nanoparticle suspensions|| |
(8 years from now)
Ilevro is owned by Novartis.
Ilevro contains Nepafenac.
Ilevro has a total of 3 drug patents out of which 0 drug patents have expired.
Ilevro was authorised for market use on 16 October, 2012.
Ilevro is available in suspension/drops;ophthalmic dosage forms.
The generics of Ilevro are possible to be released after 31 March, 2032.
Market Authorisation Date: 16 October, 2012
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic